We’re looking for SAP developers to join our Global IT Department
Are you looking to take the next step in your career? Our global IT department has new SAP developer positions available!
Search
Interview with Michael Schmelmer
"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Application Platform Data privacy statement
(Application Platform) Data Privacy Statement | Boehringer Ingelheim Careers and Job Opportunities
Helping a Local Community in a Time of Need
Helping a Local Community in a Time of Need
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Celebrating the power of people and their experiences: Observations for Hispanic/ Latinx Heritage Month
Our Boehringer colleagues share how their experiences with their culture have influenced their approach to life and work.
Women Inspiring Women: 5 questions for 6 women
Women Inspiring Women: 5 questions for 6 women
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)
Boehringer Ingelheim and Junior Achievement: A decade of inspiring futures
Boehringer Ingelheim celebrates its decade-long partnership and volunteering milestone.
Making Toys for Shelter Animals | Boehringer Ingelheim US
Find out how nearly 400 Boehringer Ingelheim employees came together to make toys out of donated t-shirts for animals living in shelters across the USA.
Canine Lyme Disease: What You Need to Know | Boehringer Ingelheim US
Click here to discover all you need to know about lyme disease in dogs; causes, symptoms, prevention, detection and treatment.
Shelter Bowl: These pets looking for a new home were the big winners
Dogs and cats in a pair of shelters were met with generous donations – and some footballs - thanks to a program committed to improving their future and well-being.
A day of giving back at Pegasus Therapeutic Riding
Take a look at our volunteer day spent refreshing a farm committed to equine therapy.
Supply Chain Scholarship for Cowtribe
A supply chain course we sponsored boosted the career of Latifa Saaka
Growing fresh produce for a cause at our U.S. headquarters
Growing fresh produce for a cause at our U.S. headquarters
2024 HBA Luminary from Boehringer Ingelheim recognized for putting patients first
Nicole Forman receives notable award for her commitment to health equity.
Yankees Legend Bernie Williams and Celebrity Vocal Coach Eric Vetro Harness the Power of Music with Tune In To Lung Health® for Interstitial Lung Disease Awareness
An extension of Boehringer Ingelheim’s Breathless® campaign, Tune In To Lung Health explores how music and breathing may help motivate, inspire, and support people living with interstitial lung disease (ILD) Program resources introduced during September’s
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
IT at BI
Discover firsthand what IT does at BI #IdoIT
Data Career
Data science at Boehringer Ingelheim is more than just solving fascinating problems. A chance to provide innovative solutions that bring value and hope to people.
Foot & Mouth Disease: Know the Facts | Boehringer Ingelheim US
Click here to read more on how the US is planning to create a vaccine bank to guard against and prevent foot-and-mouth disease in livestock across the USA.
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Big Little Things: In cancer, small things make a big impact
Little things can be a big deal when you are living with or treating cancer. “Big Little Things” celebrates the small things that have a big impact.
U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag
U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag